Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Conjugate Vaccines Market, by Region, 2019-2029 (USD Billion)
1.2.2. Conjugate Vaccines Market, by Type, 2019-2029 (USD Billion)
1.2.3. Conjugate Vaccines Market, by Disease Indication, 2019-2029 (USD Billion)
1.2.4. Conjugate Vaccines Market, by Pathogen Type, 2019-2029 (USD Billion)
1.2.5. Conjugate Vaccines Market, by End User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Conjugate Vaccines Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Conjugate Vaccines Market Dynamics
3.1. Conjugate Vaccines Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising Government Approvals for Conjugate Vaccines
3.1.1.2. Rising Prevalence of Pneumococcal Disease
3.1.2. Market Challenges
3.1.2.1. Rising side effects associated with the conjugate vaccine
3.1.3. Market Opportunities
3.1.3.1. Constant R&D activities for the development of effective vaccines
Chapter 4. Global Conjugate Vaccines Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Conjugate Vaccines Market, by Type
6.1. Market Snapshot
6.2. Global Conjugate Vaccines Market by Type, Performance - Potential Analysis
6.3. Global Conjugate Vaccines Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Conjugate Vaccines Market, Sub Segment Analysis
6.4.1. Monovalent Conjugate Vaccines
6.4.2. Multivalent Conjugate Vaccines
Chapter 7. Global Conjugate Vaccines Market, by Disease Indication
7.1. Market Snapshot
7.2. Global Conjugate Vaccines Market by Disease Indication, Performance - Potential Analysis
7.3. Global Conjugate Vaccines Market Estimates & Forecasts by Disease Indication 2019-2029 (USD Billion)
7.4. Conjugate Vaccines Market, Sub Segment Analysis
7.4.1. Pneumococcal
7.4.2. Influenza
7.4.3. Diphtheria Tetanus and Pertussis (DTP)
7.4.4. Meningococcal
7.4.5. Others
Chapter 8. Global Conjugate Vaccines Market, by Pathogen Type
8.1. Market Snapshot
8.2. Global Conjugate Vaccines Market by Pathogen Type, Performance - Potential Analysis
8.3. Global Conjugate Vaccines Market Estimates & Forecasts by Pathogen Type 2019-2029 (USD Billion)
8.4. Conjugate Vaccines Market, Sub Segment Analysis
8.4.1. Bacterial Conjugate Vaccine
8.4.2. Viral Conjugate Vaccine
8.4.3. Combination (Viral and Bacterial) Conjugate Vaccine
Chapter 9. Global Conjugate Vaccines Market, by End User
9.1. Market Snapshot
9.2. Global Conjugate Vaccines Market by End User, Performance - Potential Analysis
9.3. Global Conjugate Vaccines Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
9.4. Conjugate Vaccines Market, Sub Segment Analysis
9.4.1. Pediatrics
9.4.2. Adults
Chapter 10. Global Conjugate Vaccines Market, Regional Analysis
10.1. Conjugate Vaccines Market, Regional Market Snapshot
10.2. North America Conjugate Vaccines Market
10.2.1. U.S. Conjugate Vaccines Market
10.2.1.1. Type breakdown estimates & forecasts, 2019-2029
10.2.1.2. Disease Indication breakdown estimates & forecasts, 2019-2029
10.2.1.3. Pathogen Type breakdown estimates & forecasts, 2019-2029
10.2.1.4. End User breakdown estimates & forecasts, 2019-2029
10.2.2. Canada Conjugate Vaccines Market
10.3. Europe Conjugate Vaccines Market Snapshot
10.3.1. U.K. Conjugate Vaccines Market
10.3.2. Germany Conjugate Vaccines Market
10.3.3. France Conjugate Vaccines Market
10.3.4. Spain Conjugate Vaccines Market
10.3.5. Italy Conjugate Vaccines Market
10.3.6. Rest of Europe Conjugate Vaccines Market
10.4. Asia-Pacific Conjugate Vaccines Market Snapshot
10.4.1. China Conjugate Vaccines Market
10.4.2. India Conjugate Vaccines Market
10.4.3. Japan Conjugate Vaccines Market
10.4.4. Australia Conjugate Vaccines Market
10.4.5. South Korea Conjugate Vaccines Market
10.4.6. Rest of Asia Pacific Conjugate Vaccines Market
10.5. Latin America Conjugate Vaccines Market Snapshot
10.5.1. Brazil Conjugate Vaccines Market
10.5.2. Mexico Conjugate Vaccines Market
10.6. Rest of The World Conjugate Vaccines Market
Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. Novartis AG
11.2.1.1. Key Information
11.2.1.2. Overview
11.2.1.3. Financial (Subject to Data Availability)
11.2.1.4. Product Summary
11.2.1.5. Recent Developments
11.2.2. Neuron Biotech
11.2.3. Serum Institute of India
11.2.4. Pfizer, Inc.
11.2.5. Sanofi Pasteur
11.2.6. Bharat Biotech
11.2.7. Biological E Ltd.
11.2.8. GlaxoSmithKline, plc.
11.2.9. Merck and Company
11.2.10. CSL Limited
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
12.3. Research Assumption